/

Cullgen

Develops targeted protein degradation therapies for cancer and inflammation.

BiotechnologyPharmaceuticals cullgen.com ↗

Company facts

Founded: 2018
Employees: 115
Headquarters: United States
Type: Private
Funding: Series C · $40M · 2023